[1]索妮 杨艳敏.心房颤动合并慢性冠状动脉综合征的抗栓治疗进展[J].心血管病学进展,2022,(1):30-32.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
 SUO Ni,Y ANG Yanmin.Antithrombotic Therapy for Atrial Fibrillation Complicated with Chronic Coronary Syndrome[J].Advances in Cardiovascular Diseases,2022,(1):30-32.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
点击复制

心房颤动合并慢性冠状动脉综合征的抗栓治疗进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年1期
页码:
30-32
栏目:
出版日期:
2022-01-25

文章信息/Info

Title:
Antithrombotic Therapy for Atrial Fibrillation Complicated with Chronic Coronary Syndrome
作者:
索妮 杨艳敏
(北京协和医学院 中国医学科学院 阜外医院急重症中心,北京 100037)
Author(s):
SUO NiY ANG Yanmin
(Emergency and Intensive Care Center,Fuwai Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100037,China)
关键词:
心房颤动慢性冠状动脉综合征抗栓治疗
Keywords:
Atrial fibrillationChronic coronary syndromeAntithrombotic therapy
DOI:
10.16806/j.cnki.issn.1004-3934.2022.01.008
摘要:
心房颤动和慢性冠状动脉综合征常合并存在,二者并存时不仅增加卒中和体循环栓塞风险,且心脏缺血事件风险亦高。对于心房颤动合并慢性冠状动脉综合征患者,采取何种抗栓策略及如何权衡缺血及出血风险是临床上亟待明确的问题。近年来针对抗栓治疗的研究越来越多,现结合最新研究证据就心房颤动合并慢性冠状动脉综合征的抗栓治疗做一综述。
Abstract:
Atrial fibrillation and chronic coronary syndrome(CCS) often coexist. When they coexist,they not only increase the risk of stroke and systemic embolism,but also increase the risk of cardiac ischemic events. For patients with atrial fibrillation complicated with CCS,what antithrombotic strategy to take and how to balance the risk of ischemia and bleeding are urgent problems in clinic. In recent years,more and more studies on antithrombotic therapy have been carried out. Combined with the latest research evidence,this paper reviews the antithrombotic therapy of atrial fibrillation complicated with CCS.

参考文献/References:

[1] Kralev S,Schneider K,Lang S,et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography[J]. PLoS One,2011,6(9):e24964.

[2] 周胜华. 心房颤动 (7)冠心病合并心房颤动的治疗(续完)[J]. 中国循环杂志,2013,28(5):327-329.

[3] Steensig K,Olesen KKW,Thim T,et al. CAD is an independent risk factor for stroke among patients with atrial fibrillation[J]. J Am Coll Cardiol,2018,72(20):2540-2542.

[4] Choi HI,Ahn JM,Kang SH,et al. Prevalence,management,and long-term(6-year) outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents[J]. JACC Cardiovasc Interv,2017,10(11):1075-1085.

[5] van Rein N,Heide-Jorgensen U,Lijfering WM,et al. Major bleeding rates in atrial fibrillation patients on s ingle,dual,or triple antithrombotic therapy[J]. Circulation,2019,139(6):775-786.

[6] 吴双,杨艳敏. 心房颤动合并急性冠状动脉综合征的抗血栓治疗进展[J]. 心血管病学进展,2017,38(5):499-502.

[7] Lamberts M,Gislason GH,Lip GY,et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant:a nationwide cohort study[J]. Circulation,2014,129(15):1577-1585.

[8] Fischer Q,Georges JL,le Feuvre C,et al. Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation:“OLTAT registry”[J]. Int J Cardiol,2018,264:64-69.

[9] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS)[J]. Eur Heart J,2021,42(5):373-498.

[10] Hurlen M,Abdelnoor M,Smith P,et al. Warfarin,aspirin,or both after myocardial infarction[J]. N Engl J Med,2002,347(13):969-974.

[11] van Es RF,Jonker JJ,Verheugt FW,et al. Aspirin and coumadin after acute coronary syndromes(the ASPECT-2 study):a randomised controlled trial[J]. Lancet,2002,360(9327):109-113.

[12] Eikelboom JW,Connolly SJ,Bosch J,et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med,2017,377(14):1319-1330.

[13] Lemesle G,Ducrocq G,Elbez Y,et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation:association with ischemic and bleeding events[J]. Clin Cardiol,2017,40(10):932-939.

[14] Hamon M,Lemesle G,Tricot O,et al. Incidence,source,determinants,and prognostic impact of major bleeding in outpatients with stable coronary artery disease[J]. J Am Coll Cardiol,2014,64(14):1430-1436.

[15] Patti G,Pecen L,Lucerna M,et al. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy—A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries[J]. Int J Cardiol,2018,270:160-166.

[16] Matsumura-Nakano Y,Shizuta S,Komasa A,et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation[J]. Circulation,2019,139(5):604-616.

[17] Yasuda S,Kaikita K,Akao M,et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease[J]. N Engl J Med,2019,381(12):1103-1113.

[18] Seivani Y,Abdel-Wahab M,Geist V,et al. Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents[J]. Clin Res Cardiol,2013,102(11):799-806.

[19] Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J,2020,41(3):407-477.

[20] Steffel J,Collins R,Antz M,et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace,2021,23(10):1612-1676.

[21] Angiolillo DJ,Bhatt DL,Cannon CP,et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention:A North American Perspective:2021 Update[J]. Circulation,2021,143(6):583-596.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
 HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
 DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
 ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
 ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
 HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
 WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
 XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
 ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(1):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
 WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(1):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
 ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(1):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]

更新日期/Last Update: 2022-02-17